DISCONTINUATION RATE OF TOFACITINIB AS MONOTHERAPY IS SIMILAR COMPARED TO COMBINATION THERAPY WITH METHOTREXATE IN RHEUMATOID ARTHRITIS PATIENTS: POOLED DATA FROM TWO RHEUMATOID ARTHRITIS REGISTRIES IN CANADA

M. Movahed 1, D. Choquette 2, L. Coupal 3, A. Cesta 4, X. Li 5, E. Keystone 4, C. Bombardier 6 on behalf of ORBI and RHUMADATA Investigators. 1UHN, Toronto General Hospital Research Institute, Toronto, Canada; 2Institut de Recherche en rhumatologie et en dialyse, Montréal, Montréal, Canada; 3University of Toronto, Medicine, Toronto, Canada

Background: Tofacitinib (TOF) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). We previously reported the similarity in retention between TOFA mono-therapy and TOFA with MTX using data from two different registries separately; the Ontario Best Practices Research Initiative (OBRI) and the Quebec registry RHUMADATA.

Objectives: To increase the study power, we propose to evaluate the discontinuation rate (due to any reason) of TOFA with and without MTX, using pooled data from these two registries.

Methods: RA patients enrolled in the OBRI and RHUMADATA initiating their TOFA between 1st June 2014 (TOFA approval date in Canada) and 31st Dec 2019 were included. Concurrent MTX use was defined as MTX use for more than 75% of the time while using TOFA. Multiple imputation (imputation Chained Equation method, N=20) was used to deal with missing data for covariates at treatment initiation.

Time to discontinuation was assessed using Cox regression models. To deal with initiation.

Results: A total of 493 patients were included. Of those, 244 (49.5%) and 249 (51.5%) were treated with MTX and without MTX, respectively. Compared to TOFA monotherapy, the TOFA with MTX group had a significantly lower mean HAQ-Di, fatigue score, and the number of prior biologic use at the time of TOFA initiation. A lower proportion of positive ACPA (59% vs. 66%), prevalence of hypertension (31% vs. 37%), and concomitant use of Leflunomide (11% vs. 23%) were also observed with patients using TOFA with MTX.

Over a mean follow-up of 19.0 months, discontinuation was reported in 182 (36.9%) of all TOFA patients. After adjusting for propensity score quantile across 20 imputed datasets, there was no significant difference in discontinuation between treatment groups (adjusted HRs: 1.12, 95% CI: 0.83-1.51; p=0.49).

Conclusion: In this pooled real-world data study, we found that in patients with RA, the retention of TOFA is similar if it is used as monotherapy or in combination with MTX.
**Table 1. Outcomes at 12 months among patients with RA who initiated the first biologic**

<table>
<thead>
<tr>
<th></th>
<th>Moderate-RA (n=264)</th>
<th>Severe-RA (n=219)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remission, n (%)</td>
<td>111 (50)</td>
<td>45 (23)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Low disease activity, n (%)</td>
<td>151 (59)</td>
<td>74 (35)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Change in DAS from baseline ≥ 1.2, n (%)</td>
<td>168 (66)</td>
<td>164 (78)</td>
<td>0.7974</td>
</tr>
<tr>
<td>Change in DAS28 from baseline, mean (SD)</td>
<td>-1.4 (1.3)</td>
<td>-2.2 (1.5)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Change in HAQ-DI from baseline, mean (SD)</td>
<td>-0.29 (0.57)</td>
<td>-0.30 (0.66)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Change in DAS28 from baseline, mean (SD)</td>
<td>-0.98 (3.2)</td>
<td>-1.11 (3.2)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Change in DAS28 from baseline, mean (SD)</td>
<td>-0.85 (3.6)</td>
<td>-1.05 (3.9)</td>
<td>0.0004</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** Nancy Guo: None declared, Xuying Li: None declared, Mohammad Movahedi: None declared, Angela Cena: None declared, Claire Bombardier: Grant/research support from: OBRII was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Aurora, Bristol-Meyers Squibb, Celgene, Hospira, Janssen, Lilly, Medexus, Merck, Novartis, Pfizer, Roche, Sanofi, & UCB.

**Acknowledgement:** Dr. Bombardier held a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology

**DOI:** 10.1136/annrheumdis-2021-eular.1125

**POS0450 INCIDENCE RATES OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS IN REAL-WORLD CLINICAL PRACTICE**

Y. Hirano1, J. Hasegawa1, H. Kosugiya2, D. Khira3, K. Hattori4, Toyohashi Municipal Hospital, Rheumatology, Toyohashi, Japan; 2Nagoya University Graduate School of Medicine, Orthopaedic Surgery and Rheumatology, Nagoya, Japan

**Background:** A definition of difficult-to-treat rheumatoid arthritis (D2T RA) was recently proposed by the European League Against Rheumatism (EULAR) [1]. However, information on the incidence rates of D2T RA in real-world clinical practice is lacking.

**Objectives:** The aim of this retrospective cross-sectional study was to evaluate the incidence rates of D2T RA in clinical practice in Japan.

**Methods:** Data from the Toyohashi RA database (TRAD) was used. The TRAD is a collection of single-center retrospective data. Patients with RA who fulfilled the following three requirements were included in this study: (1) had been treated with >1 biological or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD); (2) ≥1 year had passed since b/tsDMARD treatment was initiated; and (3) regularly visited our institute at the time of investigation. The number of targeted patients was 363. The criteria of D2T RA used in this study were modified from the EULAR definition for simplification of the investigation as follows: (a) ≥2 b/tsDMARDs with different mechanisms of action had been administered; (b) at least moderate disease activity (DAS28-ESR > 3.2 or clinical disease activity index [CDAI] > 10) at the time of investigation; and (c) ≥75% of day of prednisolone (PSL) or more was administered at the time of investigation. In this study, D2T RA was defined as criteria (a) + (b) or criteria (a) + (c) or (a) + (b) + (c). The 363 patients were categorized into four groups as follows: group A, D2T RA; group B, patients with RA who had been treated with ≥2 b/tsDMARDs and did not fulfill the D2T RA definition; group C, RA patients who had been treated with one kind of b/tsDMARD with the same mechanism of action (e.g., two kinds of tumor necrosis factor inhibitors) and fulfilled either or both criteria (b) and (c); and group D, patients with RA who had been treated with one kind of b/tsDMARD with the same mechanism of action (e.g., a tumor necrosis factor inhibitors or two interleukin 6 inhibitors) and did not fulfill either or both criteria (b) and (c). The incidence rates of D2T RA were calculated, and the patients' characteristics at the time of initiation of the b/tsDMARD treatment were compared between the groups.

**Results:** The number of patients in groups A, B, C, and D were 34, 53, 94, and 168, respectively. Of all the patients included in this study, 9.4% were categorized into group A, those with D2T RA, and 39.1% were treated with ≥2 b/tsDMARDs and categorized into group A (Fig 1). The patients' age ranged from 18 to 90 years. The inclusion criteria were: a diagnosis of RA verified based on the ACR/EULAR 2010. The patients' age ranged from 18 to 90 years. The group comprised 30 conventionally healthy individuals. The inclusion criteria were: a diagnosis of RA verified based on the American College of Rheumatology/European Anti-Rheumatic League (ACR/EULAR) 2010. The patients' age ranged from 18 to 90 years. The group comprised 30 conventionally healthy individuals.

**Discussion:** The normal level of fetuin-A was calculated using the formula M±2 SD and was compared with the control group. The normal level of fetuin-A was calculated using the formula M±2 SD and was compared with the control group. The normal level of fetuin-A was calculated using the formula M±2 SD and was compared with the control group. The normal level of fetuin-A was calculated using the formula M±2 SD and was compared with the control group.

**Disclosure of Interests:** None declared

**REFERENCES:**


**POS0451 SERUM FETUIN-A AND VISFATIN LEVELS IN WOMEN WITH RHEUMATOID ARTHRITIS DEPENDING ON DISEASE ACTIVITY**

Y. Akhverdyran1, B. Zavadovsky1, E. Papichev1, J. Polyakova1, L. Seewordova1,

1Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology named after A.B. Zorovskiy», Joint Diseases Treatment and Prevention Laboratory, Volgograd, Russian Federation

**Background:** In recent years, the systemic effects of a number of cytokines have been actively studied, in particular, fetuin-A is considered a negative protein of the acute phase response, and visfatin, on the contrary, affects the activation of the cytokine cascade and has a pro-inflammatory effect. Taking into account that women suffer from rheumatoid arthritis (RA) more often, we investigated the levels of fetuin-A and visfatin in the blood serum of females in comparison with a group of healthy individuals and depending on the activity of the disease.

**Objectives:** To study the levels of fetuin-A and visfatin in the blood serum of women suffering from RA, depending on the activity of the disease.

**Methods:** The study included 110 women with RA and 30 apparently healthy individuals. The inclusion criteria were: a diagnosis of RA verified based on the criteria of the American College of Rheumatology/European Anti-Rheumatic League (ACR/EULAR) 2010. The patients' age ranged from 18 to 90 years. The control group included 30 conventionally healthy individuals. Serum fetuin-A and visfatin levels were determined by indirect enzyme-linked immunosorbent assay using commercial kits. RA activity was determined by the DAS28-ESR index. Activity O was in 33 (30%) patients, grade II in 67 (60.9%), grade III in 10 (9.09%) patients.

**Results:** The normal level of fetuin-A was calculated using the formula M±2 SD in the group of conventionally healthy individuals and ranged from 653.55 to 972.19 μg/ml. In patients with grade 0-1 RA activity according to DAS28, the mean serum fetuin-A level was 843.92±130.73 μg/ml in patients with grade II activity, 742.37±88.65 μg/ml, with grade III activity of disease activity - 663.9±123.7 μg/ml (p<0.001). The average level of visfatin in the blood serum in healthy individuals was 2.43±0.17 ng/ml. The level of normal values of visfatin in healthy individuals, defined as 2.40-20, ranged from 0 to 5.07 ng/ml. The average level of visfatin in patients with RA was 6.27±0.16 ng/ml, which is significantly higher than in healthy individuals (p<0.001).

In patients with 0-1 degree of RA activity according to DAS28, the average level of visfatin in blood serum was 4.94±0.02 ng/ml, in patients with degree II activity - 5.08±0.02 ng/ml, with degree III activity of disease activity - 6.82±0.23 ng/ml (p<0.001).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2021-eular.1221